|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 1/20/2021 2:00:13 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Fighting Climate Change through Biotechnology Innovation
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
Foreign Agricultural Biotechnology Laws and Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Funding for the USDA
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Genetically Engineered (GE) Plants
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)
---EPA Regulatory Approach to Gene Editing
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
The United States-Mexico-Canada Agreement (USMCA)
---Ag-Biotech Provisions
US-China Trade Agreement
---Ag-Biotech Provisions
US-UK Trade Agreement
---Ag-Biotech Provisions
USDA/APHIS Agricultural Biotechnology Regulations
---Regulatory Treatment of Gene Edited Products
---Implementation of the SECURE Rule under the Plant Protection Act
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Natl Economic Council (NEC), Food & Drug Administration (FDA), White House Office, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Matthew |
O'Mara |
|
|
|
Shea |
Hartley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Dana |
O'Brien |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
Funding for Antimicrobial Resistance Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biofuels
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Incentives for Sustainable Aviation Fuels
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
Funding for Biomass Crop Assistance Program
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for Biorefineries
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
Funding for FDA
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP)
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for National Institutes of Health
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Renewable Chemicals/Bio-based Products
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for the USDA
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.8879: Renewable Chemicals Act of 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---Bayh-Dole 40th Anniversary
---March-In Rights
---NIST Proposed Rulemaking on Bayh-Dole
---State Attorney General Letter
Compulsory licensing
---H.R.465/S.102: Prescription Drug Price Relief Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S.2387: We Protect American Investment in Drugs Act of 2019
Diversity in Patenting
---S.4394: Inventor Diversity for Economic Advancement (IDEA) Act of 2020
Drug Patenting
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
Inter Partes Review
Intellectual Property International Enforcement
---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes.
---India
Patent Reform
---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020
---Patent Litigation Reforms
Patenting of Biological Inventions
---35 USC Section 101 on Patent Eligibility
The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions
US-China Trade Agreement
---IP Provisions
US-UK Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Natl Institute of Standards & Technology (NIST)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---General
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Erick |
Lutt |
|
|
|
Claire |
Brandewie |
|
|
|
Dana |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act of 2020
---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020
---H.R.8769: The Sustainable Aviation Fuel Act
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Incentives for Sustainable Aviation Fuels
---One-year extension of the Second-generation Biofuel Producer Tax Credit and Two-year Extension of the Section 45Q Credit for Carbon Dioxide Sequestration in H.R. 133: Consolidated Appropriations Act for FY 2021
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Incentives for Sustainable Aviation Fuels
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
Funding for Biomass Crop Assistance Program
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for Biorefineries
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
RFS (Renewable Fuel Standard)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Cellulosic Registration Applications for Corn Kernel Fiber
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021
---International Consistency of Regulation for Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Economic Council (NEC), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Dana |
O'Brien |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act of 2020
---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020
---H.R.8769: The Sustainable Aviation Fuel Act
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Incentives for Sustainable Aviation Fuels
---One-year extension of the Second-generation Biofuel Producer Tax Credit and Two-year Extension of the Section 45Q Credit for Carbon Dioxide Sequestration in H.R. 133: Consolidated Appropriations Act for FY 2021
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Incentives for Sustainable Aviation Fuels
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
Funding for Biomass Crop Assistance Program
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for Biorefineries
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021
RFS (Renewable Fuel Standard)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Cellulosic Registration Applications for Corn Kernel Fiber
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
340B Drug Discount Program
---Program Implementation & Oversight
Biodefense Research, Development and Procurement Issues (Nonfunding)
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
Biosimilars
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---Biosimilar Copay
---Reimbursement
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020
---H.R.8080: Health STATISTICS Act of 2020
---S.4317: SAFE TO WORK Act
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Drug Supply Chain Management
---Immunization information systems
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---In-Home Administration of Part B Drugs
---Operation Warp Speed
---Patient Cost-Sharing and Smoothing
---PREP Act COVID-19 declaration coverage for private sector procurement
---Preventive Monoclonal Antibody Coverage
Diversity & Inclusion
Drug Evaluation and Review
---COVID-19 Lessons Learned
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Priority Review Voucher Programs
Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---General
Drug Manufacturing, Quality & Distribution
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.7767: To amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment
---Drug Shortages
---Executive Order on Buy American
Drug Patenting
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
Drug Pricing
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1425: The Patient Protection and Affordable Care Enhancement Act of 2020
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO)
---General
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---International Pricing Index Proposal
---Most Favored Nation (MFN) Model interim final rule (MFN Rule)
Funding for Antimicrobial Resistance Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.4760:Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for FDA
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP)
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Funding for National Institutes of Health
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule
Orphan Drug Issues
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019
---H.R.4712: Fairness in Orphan Drug Exclusivity Act of 2019
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Rare Pediatric Disease Priority Review
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
Reimbursement and Coverage of Innovative Products
---H.R.3: Lower Drug Costs Now Act of 2019
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---Administration Rebate Rule
---CMMI Authority
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients
---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, MFN EO)
---In-Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Contracting and Communications
---Value-Based Purchasing (VBP) Rule
The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions
US-China Trade Agreement
---IP Provisions
US-UK Trade Agreement
---IP Provisions
Vaccine Injury Compensation Program Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
Vaccines and Infectious Diseases
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Adult Immunization Education
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Maternal Immunization
---Operation Warp Speed
---Preventive Monoclonal Antibody Coverage
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), White House Office, Natl Economic Council (NEC), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Aiken |
Hackett |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Claire |
Brandewie |
|
|
|
Cartier |
Esham |
|
|
|
Matthew |
O'Mara |
|
|
|
Camelia |
Thompson |
|
|
|
Danielle |
Friend |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Nonfunding)
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
Funding for Antimicrobial Resistance Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Shea |
Hartley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Nonfunding)
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020
---H.R.8080: Health STATISTICS Act of 2020
---COVID-19 Pricing-Related Provisions
---Drug Supply Chain Management
---Immunization information systems
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---In-Home Administration of Part B Drugs
---Patient Cost-Sharing and Smoothing
---Preventive Monoclonal Antibody Coverage
Funding for Antimicrobial Resistance Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for National Institutes of Health
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Shea |
Hartley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
Coronavirus (COVID-19) Pandemic
---H.R.4100/S.1712: DISARM Act of 2019
---COVID-19 Pricing-Related Provisions
---Immunization information systems
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---In-Home Administration of Part B Drugs
---Patient Cost-Sharing and Smoothing
---Preventive Monoclonal Antibody Coverage
Drug Pricing
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO)
---General
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---International Pricing Index Proposal
---Most Favored Nation (MFN) Model interim final rule (MFN Rule)
Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule
Reimbursement and Coverage of Innovative Products
---H.R.3: Lower Drug Costs Now Act of 2019
---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021
---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act
---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---Administration Rebate Rule
---CMMI Authority
---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO)
---In-Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Most Favored Nation (MFN) Model interim final rule (MFN Rule)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Contracting and Communications
---Value-Based Purchasing (VBP) Rule
Vaccines and Infectious Diseases
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
David |
Lachmann |
|
|
|
Shea |
Hartley |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Incentives
---H.R.7505: American Innovation Act of 2020
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7555: The More Cures Act of 2020
---H.R.7556: Start-Ups for Cures Act
---H.R.7917: IGNITE American Innovation Act
---S.1249: American Innovation Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Introduction of IGNITE American Innovation Act in Senate
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
---Reform of Net Operating Loss Rules
Capital Market Enhancements
---Amended Definition of Smaller Reporting Company
Coronavirus (COVID-19) Pandemic
---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020
---H.R.7917: IGNITE American Innovation Act
---Introduction of IGNITE American Innovation Act in Senate
Coronavirus (COVID-19) Small Business Loans (Non-Funding)
---Affiliation
---Eligibility
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
Sarbanes Oxley Section 404 (b)
---H.R.3886/S.452: Fostering Innovation Act of 2019
---Implementation of Jumpstart Our Business Startups (JOBS) Act of 2012
Small Business Innovation Research (SBIR) Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Cameron |
Arterton |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
Aiken |
Hackett |
|
|
|
Cartier |
Esham |
|
|
|
Claire |
Brandewie |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit
Capital Formation Incentives
---H.R.7505: American Innovation Act of 2020
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7555: The More Cures Act of 2020
---H.R.7556: Start-Ups for Cures Act
---H.R.7917: IGNITE American Innovation Act
---S.1249: American Innovation Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Introduction of IGNITE American Innovation in the Senate
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
---Reform of Net Operating Loss Rules
---Securities Regulations (13F, Exempt Offerings, Market Liquidity)
Coronavirus (COVID-19) Pandemic
---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020
---H.R.7917: IGNITE American Innovation Act
---Introduction of IGNITE American Innovation in the Senate
Research & Development Tax Credit Reforms
---H.R.4549: American Innovation and Competitiveness Act (AICA) of 2019
---H.R.7767: To amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment.
---Expensing of R&D Expenditures
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---R&D Payroll Credit
Vaccine Injury Compensation Program Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cameron |
Arteron |
|
|
|
Michael |
Mattoon |
|
|
|
Aiken |
Hackett |
|
|
|
Cartier |
Esham |
|
|
|
Claire |
Brandewie |
|
|
|
Jamie |
Gregorian |
|
|
|
Shea |
Hartley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
CFIUS and Foreign Investment
---Implementation of Foreign Investment Risk Review Modernization Act (FIRRMA) of 2017
Digital Trade
---EU Digital Strategy
Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---General
Drug Pricing
---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO)
---International Pricing Index Proposal
---Most Favored Nation (MFN) Model interim final rule (MFN Rule)
Foreign Agricultural Biotechnology Laws and Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Genetically Engineered (GE) Animals
---International Consistency of Regulation for Gene Edited Products
Genetically Engineered (GE) Plants
---International Consistency of Regulation for Gene Edited Products
Intellectual Property International Enforcement
---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes.
---India
The United States-Mexico-Canada Agreement (USMCA)
---Ag-Biotech Provisions
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions
US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions
US-UK Trade Agreement
---Ag-Biotech Provisions
---IP Provisions
---Market Access
World Health Organization (WHO)
---United States Withdrawal from the World Health Organization (WHO)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Commerce - Dept of (DOC), State - Dept of (DOS), Patent & Trademark Office (PTO), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Cameron |
Arterton |
|
|
|
Aiken |
Hackett |
|
|
|
Erick |
Lutt |
|
|
|
Matthew |
O'Mara |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Engineering Biology
---H.R.4373 Engineering Biology Research and Development Act
---S.3734: Bioeconomy Research and Development Act of 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Michael |
Mattoon |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |